Your browser doesn't support javascript.
loading
Evaluation of the safety, pharmacokinetics and treatment effects of an alpha(nu)beta(3) integrin inhibitor on bone turnover and disease activity in men with hormone-refractory prostate cancer and bone metastases.
Rosenthal, Mark A; Davidson, Peter; Rolland, Frederic; Campone, Mario; Xue, Lingling; Han, Tae H; Mehta, Anish; Berd, Yuliya; He, Weili; Lombardi, Antonio.
Affiliation
  • Rosenthal MA; Royal Melbourne Hospital, Melbourne, Australia. mark.rosenthal@mh.org.au
Asia Pac J Clin Oncol ; 6(1): 42-8, 2010 Mar.
Article in En | MEDLINE | ID: mdl-20398037
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Bone and Bones / Bone Neoplasms / Integrins / Bone Density Conservation Agents Type of study: Clinical_trials Limits: Aged / Humans / Male / Middle aged Language: En Journal: Asia Pac J Clin Oncol Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Australia Country of publication: Australia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prostatic Neoplasms / Bone and Bones / Bone Neoplasms / Integrins / Bone Density Conservation Agents Type of study: Clinical_trials Limits: Aged / Humans / Male / Middle aged Language: En Journal: Asia Pac J Clin Oncol Journal subject: NEOPLASIAS Year: 2010 Document type: Article Affiliation country: Australia Country of publication: Australia